In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
|Articles|May 25, 2011
Wes Wheeler Appointed as CEO by Marken's Board of Directors
Advertisement
The
Marken’s Board and executive management team have sought to add an executive such as Mr. Wheeler for his in depth of experience in the life science industry as well as a strong background in logistics to further strengthen market leadership and maintain Marken’s growth path.
Prior to joining Marken, Wes held the title of President and CEO of Patheon Inc., a contract manufacturing services company. Wes was also a former President of Valeant Pharmaceuticals International, and has previously held senior executive roles of increasing responsibility in manufacturing, marketing and engineering at GlaxoSmithKline, plc. Preceding his 22 year career in pharmaceuticals, Mr. Wheeler had a successful 12 year career at ExxonMobil. He holds a bachelor’s degree in Mechanical Engineering and aMasters of Business Administration.
“As the nature of biopharmaceutical R&D changes, well controlled clinical supply chains will be a significant factor in the success of key life science companies and the industries that support them. The Board and I feel that Wes can bring his experience from the drug manufacturing, biotechnology, and traditional pharmaceutical industries to augment an already strong management team and continue Marken’s growth”, said Gerard Barba,Marken’s Chairman.
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Where AI Governance in Clinical Development Falls Short
5